medwireNews: The US FDA has authorized the use of durvalumab plus tremelimumab alongside first-line platinum-based chemotherapy in the metastatic non-small-cell lung cancer (NSCLC) setting.
The decision states that the triplet is indicated for adults with treatment-naïve metastatic disease and no sensitizing EGFR or ALK aberrations.
The efficacy of the triplet regimen was demonstrated in the POSEIDON trial, in which both progression-free and overall survival were significantly prolonged with the addition of durvalumab plus tremelimumab to chemotherapy.
The recommended doses of durvalumab and tremelimumab vary by patient weight, at a respective 1500 mg and 75 mg for those weighing 30 kg or more and 20 mg/kg and 1 mg/kg for those weighing less than 30 kg. In each case the drugs need to be given once every 3 weeks alongside four cycles of platinum-based chemotherapy, followed by maintenance treatment with durvalumab plus chemotherapy every 4 weeks. The FDA also says that a fifth dose of tremelimumab should be given at week 16.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group